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Germline determinants of gene expression in tumors
are infrequently studied due to the complexity of
transcript regulation caused by somatically acquired
alterations. We performed expression quantitative
trait locus (eQTL)-based analyses using the multi-
level information provided in The Cancer Genome
Atlas (TCGA). Of the factors we measured, cis-acting
eQTLs accounted for 1.2% of the total variation of
tumor gene expression, while somatic copy-number
alteration and CpG methylation accounted for 7.3%
and 3.3%, respectively. eQTL analyses of 15 previ-
ously reported breast cancer risk loci resulted in
the discovery of three variants that are significantly
associated with transcript levels (false discovery
rate [FDR] < 0.1). Our trans-based analysis identified
an additional three risk loci to act through ESR1,
MYC, and KLF4. These findings provide a more
comprehensive picture of gene expression determi-
nants in breast cancer as well as insights into the
underlying biology of breast cancer risk loci.
INTRODUCTION
Prior studies unambiguously demonstrate that inherited variation
is a determinant of gene expression (Cheung et al., 2003; Mont-
gomery et al., 2010; Pickrell et al., 2010; Schadt et al., 2003;
Stranger et al., 2005). Polymorphisms associated with mes-
senger RNA (mRNA) levels are typically referred to as expression
quantitative trait loci (eQTLs). eQTL studies have shed light onthe genetic architecture of gene expression. eQTLs have also
provided key insights into genes and pathways underlying the
associations by providing an intermediate phenotype between
non-protein-coding genetic variants and complex traits (Chen
et al., 2008; Cookson et al., 2009; Emilsson et al., 2008; Grisanzio
et al., 2012; Musunuru et al., 2010; Pomerantz et al., 2009). In
fact, trait-associated loci are enriched for eQTLs (Nicolae et al.,
2010). Most of our knowledge, however, is based on data
derived from cell lines and normal tissues (Dimas et al., 2009;
Myers et al., 2007; Nica et al., 2010). By contrast, cancer studies
typically generate more expression data on tumors than in
normal tissues.
Mapping eQTL-target gene associations in tumor tissue pres-
ents additional analytical challenges. Tumors acquire frequent
genetic and epigenetic alterations, which can substantially affect
gene expression. For example, somatic copy-number changes
and DNA methylation status are known to strongly influence
transcript abundance in tumors (Curtis et al., 2012; Portela and
Esteller, 2010). Consequently, the effect of these somatic alter-
ations may obscure the association between germline genetic
polymorphisms and gene expression. The creation of publicly
available large-scale data sets, such as The Cancer Genome
Atlas (TCGA) and Encyclopedia of DNA Elements (ENCODE),
provide comprehensive catalogs of multiple data types per-
formed on the same set of samples. In this study, we use these
resources to develop a general method that models transcript
levels as having inputs from germline and somatic factors.
eQTL-based strategies provide a straightforward method
for linking non-protein-coding risk alleles discovered through
genome-wide association studies (GWAS). Understanding the
genes and pathways underlying common risk alleles remains a
formidable challenge because the majority of trait-associated
polymorphisms are outside of known protein-coding regionsCell 152, 633–641, January 31, 2013 ª2013 Elsevier Inc. 633
(Hindorff et al., 2009). Many of these loci are thought to be
involved in transcriptional regulation (Freedman et al., 2011; Nic-
olae et al., 2010). Therefore, eQTL-based approaches are well
suited to identifying candidate genes acting through these loci.
We apply our method to known breast cancer risk alleles discov-
ered through GWAS to link the risk variants with their target
genes.
RESULTS
The results are presented in two main sections. First, a general
approach is described to identify cis-acting eQTL-target gene
pairs in tumor genomes while adjusting for other factors that
can also influence transcript abundance. Using this method,
we conducted a study to identify determinants of transcript vari-
ation in the TCGA breast cancer samples.
Next, to gain biologic insights into known breast cancer risk
polymorphisms, we hypothesized that the breast cancer risk
alleles previously discovered through GWAS are eQTLs. We
performed separate cis- and trans-based eQTL analyses for
15 previously identified risk loci in the TCGA breast cancer
data sets.
Breast Cancer Data Set
We selected 407 patients with both tumor samples andmatched
normal blood samples from the TCGA breast cancer data set.
For each of these samples, we obtained the germline genotypes
from the normal blood sample and the somatic copy number,
methylation, and mRNA gene expression measures from the
matched tumor sample (Table S1, available online). Ancestry
was inferred using genotype data resulting in 273 cases of
European ancestry. In the analyses below, 171 estrogen re-
ceptor (ER)-positive cases and 48 ER-negative cases (as deter-
mined by ESR1 expression levels) were used (Experimental
Procedures).
eQTL Analysis of ER-Positive Breast Cancer
For a given gene i and a SNP locus j, we consider three factors of
transcript abundance (T): the germline genotypes as the genetic
determinants (G), the somatic copy number alterations (Sc), and
the CpG methylation levels in the promoter region (M). We first
used multivariate linear regression (Equation 1) to compute the
residual expression εi of Sci and Mi:
Ti =Sci +Mi + εi (Equation 1)
Then we regress on the residual expression εi to the germline
genotypes Gi where ui is the random error.
εi =Gi +ui (Equation 2)
Thus, the effects of the genetic determinants, the somatic copy-
number changes, and the methylation levels on the transcript
abundance are estimated separately.
Using this model, we evaluated the association between the
germline genotypes of 816,362 SNP loci and genes within
1 Mb on either side of each SNP locus. In order to further control
the false-positive rate, we excluded 396 genes with low expres-
sion levels (less than 10% present calls—an Affymetrix quality634 Cell 152, 633–641, January 31, 2013 ª2013 Elsevier Inc.metric that determines whether a given transcript is expressed),
85 genes with probes having a known sequence polymorphism,
and the highly polymorphic human leukocyte antigen (HLA)
region. A Q-Q plot of the raw p-values corresponding to the
cis-associations tested before and after adjusting for somatic
factors suggests systematic bias in the unadjusted data (l =
1.29), which is eliminated after the adjustment (l = 0.941.01,
Figure S1).
Significant associations were determined by applying a false-
discovery rate (FDR) threshold of less than 0.1. As a result, from
8,107,200 unique SNP gene pairs we identified 6,046 associa-
tions with raw p values below 7.50 3 105. These associations
mapped to a total of 6,145 SNP loci and 1,359 unique target
genes (Table S2). The fraction of variation of the expression
levels explained by the associated cis-acting SNP loci (R2)
ranged from 18.5% to 73.2%.
Of the target genes, 689 (50.7%) are regulated by a single cis-
acting SNP locus (Figure S2A); the rest are regulated by multiple
loci (2–83). After adjusting correlated loci by stepwise feature
selection (Experimental Procedures), 664 genes (48.9%) are
explained bymultiple SNP loci (median = 4), suggesting the exis-
tence of multiple independent eQTLs. Of the 5,893 cis-acting
eQTL loci, 5,669 cis-acting eQTL loci are associated with one
target gene, suggesting that the associations are highly locus
specific (Figure S2B). cis-associations typically occur within
the two nearest transcripts (39.8%) of the eQTL; an additional
18.9% occur between the three to five nearest transcripts
(Figure S2C).
Determinants of Transcript Levels
Transcript levels of 8,568 genes (54.5% of the total genes tested)
are significantly affected by the somatic copy-number changes
in the corresponding coding regions (FDR < 0.1). Among the
1,359 target genes of the cis-acting SNP loci, 880 (64.8%) are
also significantly associated with somatic copy number. We
also identified 2,529 transcripts (16.1% of the total genes tested)
that are affected by the methylation of CpG islands in the
promoter region (FDR < 0.1). Among these genes, 210 are also
target genes of eQTLs (15.5%, Figure 1A). Of the 15,732 genes
tested, the cis-acting SNP loci account for 1.2% of the total
variance of the expression. Somatic copy-number alterations
account for 7.3% and methylation status accounts for 3.3% of
variation in gene expression (Figure 1B).
eQTL Analysis of ER-Negative Breast Cancer
To compare the genetic determinants of gene expression in
different subtypes of breast cancer, we performed a cis-eQTL
analysis for 48 ER-negative breast cancer samples. Based on
the model described above, we identified 380 significant cis-
associations (FDR < 0.1), mapping to 380 SNP loci and 179
target genes (Table S3). Notably, only 43 target genes (24.0%)
from ER-positive tumors are represented in the significant asso-
ciations in ER-negative tumors.
eQTL Analysis of Breast Cancer Risk Loci
cis-Analysis
We focused on 15 breast cancer loci previously reported by
genome-wide association studies (p < 5 3 108, Table S4)
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Figure 1. Effects of Three Determinants on
Gene Expression in ER-Positive Breast
Cancer: cis-Acting SNP Loci, Somatic
Copy Number, and CpG Methylation
(A) Venn diagram shows the number of genes that
are under regulation of one or multiple factors.
(B) Pie chart shows the relative and absolute
fraction of variance of gene expression explained
by three factors.
Please see also Figures S1 and S2 and Tables S1,
S2, S3, and S5.(Hindorff et al., 2012). We identified three significant cis-associ-
ationsmapping to risk loci at 2q35 (IGFBP5), 5q11 (C5orf35), and
16q12 (TOX3) (FDR < 0.1, Table S5).
trans Analysis
We next hypothesized that the 15 GWAS-identified risk loci
are cis-acting eQTLs of transcription factors (TFs), which in
turn influence multiple downstream targets. In such cases, the
activity level of a given TF may be more accurately reflected in
the expression levels of its target genes (Essaghir et al., 2010;
Wolfer et al., 2010). It is then possible to examine the set of
eQTL-associated genes and then work ‘‘backwards’’ to evaluate
whether a TF binding motif is enriched in the target genes (Fig-
ure 2). Thus, each risk locus will be associated with a set of target
genes. For each set of target genes, the putative enhancer
regions, as defined by ENCODE-generated DNaseI hypersensi-
tivity (DHS) data from the MCF-7 cell line (a breast cancer cell
line), were analyzed for TF DNA bindingmotif enrichment (Exper-
imental Procedures). This analysis revealed three risk loci for
which the target genes are significantly enriched for three
particular TF motifs (6q25/ESR1; 9q31/KLF4, and 8q24/MYC)
(Table 1). Moreover, as mandated by our analysis, the particular
TF whose motif is overrepresented in the target genes is physi-
cally located near the risk locus. Of note, 6 of the 15 risk loci
have a TF located nearby, but the TF motif is not enriched in
the target genes (Table S6).
The ESR1 enrichment is of particular significance as ESR1
encodes the ER, the defining TF of this class of breast cancer.
To further evaluate the ER binding sites as defined by in vivo
occupancy, we used the ER cistrome previously defined by
chromatin immunoprecipitation in MCF-7 cells (Carroll et al.,
2006). The regions within the 6q24 gene set that are computa-
tionally predicted to bind ER by the presence of an ER DNA
binding motif are significantly enriched for in vivo ER binding
sites defined by chromatin immunoprecipitation (p < 1 3 106).
Of note, the ESR1, KLF4, and MYC RNA expression levels
were not significantly associated with genotypic status. Since
TF expression levels tend to be under tight regulatory control
and are present at low cellular concentrations (Vaquerizas
et al., 2009), TFs may be difficult to detect using an eQTL-based
methodology.Cell 152, 633–641,A complementary method of identi-
fying cis-regulated genes is allelic imbal-
ance (AI). AI for a given gene can be
measured when an individual is heterozy-
gous for a transcribed polymorphism.Significant deviations from a 1:1 ratio in the maternal: paternal
RNA levels indicate genetic and/or epigenetic cis-influences
on a gene (Babak et al., 2010; Campino et al., 2008; Ge et al.,
2009; Heap et al., 2010). Recently released TCGA RNA-se-
quencing data enable evaluation of AI in tumor samples (Exper-
imental Procedures). The expectation is that individuals who are
heterozygous for the functional regulatory polymorphism (or any
variant in linkage disequilibriumwith it) will display AI in the target
gene, while homozygous individuals will demonstrate less AI
(Forton et al., 2007; Lefebvre et al., 2012) (Figure S3).
Breast cancer TCGA RNA-seq data from 177 individuals were
evaluated for the relationship between genotypic status at the
risk alleles and AI (Table S7). After removing cases with somatic
copy-number alterations, our results demonstrated that the
6q25 and 8q24 risk loci are significantly associated with allelic
specific expression of ESR1 and MYC, respectively (p = 0.017
for rs2046210/ESR1 and p = 0.035 for rs418269/MYC; Figures
3A and 3B). As expected, the AI is greatest in individuals hetero-
zygous for the risk variant. No significant association was
observed for KLF4; however, the power was limited due to fewer
informative variants in the transcribed region (Figure 3C).
To validate the computational results, we sought experimental
evidence by chromosome conformation capture (3C) to evaluate
physical interactions between the risk loci and the promoters of
the TFs. Since theMYC locus has already been shown to interact
with the 8q24 risk locus (Ahmadiyeh et al., 2010; Wright et al.,
2010; Yochum et al., 2010), we tested for interactions between
the ESR1 and KLF4 promoters and the 6q25 and 9q31 risk
regions, respectively (Experimental Procedures). In estradiol-
stimulated MCF-7 cells, we observed sequence-verified interac-
tion products for 6q25 and 9q31 at distances of 189 kb and
644 kb, respectively (Figure 4).
DISCUSSION
Most of our knowledge of the genetics of gene expression has
been derived through studies conducted in cell lines and normal
primary tissues. Understanding the germline contribution to
gene expression levels in tumors is confounded by the acquisi-
tion of complex somatic and epigenetic alterations, as well asJanuary 31, 2013 ª2013 Elsevier Inc. 635
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Figure 2. Schematic of the Hypothesis that
Risk Alleles Are cis-eQTLs of Transcription
Factors
(A) A risk locus (blue triangle) cis-regulates a tran-
scription factor (TF; red explosion).
(B and C) The mRNA of the TF is translated into its
active form (B) and binds to the target genes (C).
(D) These target genes are associated with the risk
allele, but not the TF because the TF is itself tightly
regulated.
(E) DNA sequences within DNaseI hypersensitive
sites (yellow peak) are evaluated for TF binding
motif enrichment.
Please see also Tables 1 and S5.a dearth of data sets measuring this information on a common
set of samples. Although eQTL studies using tumors have
been reported, the effects of somatic genetic and epigenetic
factors have not been addressed (Grisanzio et al., 2012; Kristen-
sen et al., 2006; Pomerantz et al., 2010). Our method provides
a practical solution to account for the multiple factors that deter-
mine gene expression levels. Moreover, the method is easily
expandable to accommodate other factors, such as somatically
acquired single-nucleotide variants, that may influence gene
expression and can be applied to the growing availability of
genome-wide tumor data sets.
The overlap of eQTL-target genes between ER-positive and
ER-negative samples is approximately 25%. Although the litera-
ture continues to emerge on this topic, this degree of eQTL
sharing is what is typically observed between different tissue
types (Dimas et al., 2009; Nica et al., 2010). The data are consis-
tent with these tumors arising from different cell types.
The breast cancer risk SNP analysis provides a workingmodel
of the biology for non-protein-coding risk alleles. Both cis-based
and trans-based analyses were performed. In the cis-analysis,
we observed three transcripts associated with three risk loci at
an FDR < 0.1 (2q35/IGFBP5, 5q11/C5orf35, and 16q12/TOX3).
Interestingly, the association with TOX3 (in the same direction)
has been previously observed, further demonstrating the utility
of publicly available data (Riaz et al., 2012). IGFBP5 is a strong
candidate gene for mediating the effect of the 2q35 risk locus.636 Cell 152, 633–641, January 31, 2013 ª2013 Elsevier Inc.In breast cancer cell lines, IGFBP5 over-
expression affected cell-cycle regulation
and apoptosis (Butt et al., 2003). In trans-
genic mice, IGFBP5 expression interferes
with mammary epithelial development
(Tonner et al., 2002). IGFBP5 expression
levels have also been shown to be a
marker of poor outcome in patients with
breast cancer (Becker et al., 2012).
Our analysis does not support the previ-
ously described association between the
10q risk locus and FGFR2 levels (p =
0.537). Prior studies have yielded incon-
sistent results with three studies demon-
strating an association and two that have
not (Huijts et al., 2011; Martin et al.,
2011; Meyer et al., 2008; Riaz et al.,2012; Sun et al., 2010). Variability between the studies may be
due to different sample sizes, different tissue types (normal,
tumor), and/or measurement of different isoforms. The largest
study was performed on 1,401 breast tumor samples and the
results showed no association. eQTL studies performed in dif-
ferent cell types and across the full spectrum of expressed iso-
forms will help to further clarify these observations.
The trans analysis for the breast cancer risk loci supports the
assertion that some risk alleles act through TFs that, in turn, influ-
ence their target genes. The data demonstrate that target genes
of a TF can be used as a surrogate readout for TF activity as has
been shown in a recent study (Small et al., 2011). For example,
8q24-associated target genes are enriched for the MYC motif,
providing an additional layer of support that MYC is a common
upstream TF. In addition to MYC, we discovered that the 6q25
and 9q31 risk loci act through the ESR1 and KLF4 TFs. Since
the TFs themselves were not associated with genotypic status
using an eQTL-based method, we turned to measuring allelic
expression of the TFs.
AI is an intuitively advantageousmethod of detecting cis-regu-
latory effects. Theoretically, correlating AI with genotypic status
should be more sensitive than eQTL-based analyses because
the comparison is made within an individual (using the other
chromosome as a control), thereby removing sources of envi-
ronmental noise (Fogarty et al., 2010). By applying AI to the
TFs and correlating the AI with genotypic status at the risk loci,
Table 1. Transcription Factors Mediating Distant Associations between Risk Loci for Estrogen Receptor-Positive Breast Cancer and
Gene Expression
Region Chr Tested SNP Physical Position
No. of Associated
Genes (p < 0.05)
p value (Target
Genes p < 0.05) TF within 1 Mb
Distance between
Risk Locus and TF (kb)
6q25.1 6 rs2046210 151990059 476 4.23 3 107 ESR1 180
8q24.21 8 rs418269 128415540 221 4.19 3 108 MYC 402
9q31.2 9 rs471467 109927934 415 6.42 3 1016 KLF4 641we demonstrated that MYC and ESR1 are significantly imbal-
anced in individuals that are heterozygous for the risk locus. A
prior report also demonstrated allelic imbalance inMYC expres-
sion levels in a colon cancer cell line heterozygous for the 8q24
colon cancer risk allele (Wright et al., 2010). KLF4 did not reveal
allelic imbalance, most likely due to the low prevalence of infor-
mative markers in the KLF4 transcript. The AI method requires
appreciable numbers of heterozygous (informative) sites in ex-
pressed transcripts. Nevertheless, KLF4 is a strong candidate
gene. In prior studies, knockdown of KLF4 in MCF-7 cells
affected proliferation, migration, and invasion (Akaogi et al.,
2009; Yu et al., 2011). In addition, KLF4 has been shown to
play apotent oncogenic role inmammary tumorigenesis bymain-
taining stem cell-like features (Yu et al., 2011). In agreement with
the importance ofKLF4 in driving stemcell features is the seminal
observation that KLF4 is one of four TFs required for generating
induced pluripotent stem cells (Takahashi et al., 2007).
eQTL-based analyses represent one strategy for detecting
how risk alleles exert their effects on gene expression. Negative
results can be attributed to biologic and technical reasons. For
example, a variant may influence expression only at a certain
developmental time point or in a non-cell-autonomous fashion.
In addition, most of the eQTL analyses are based on measures
of steady-state expression levels; however, a variant could be
influencing the non-steady-state aspect of expression, such as
rate of transcription. A negative eQTL result may also arise
from technical limitations, which can occur due to a lack of
power to detect a subtle, but biologically important, change in
transcript levels. Testing associations with other transcribed
elements, such as transcript isoforms as well as small and long
noncoding RNAs, will also be informative. Moreover, it will be
interesting to compare eQTL-target gene results in tumors with
results derived from normal tissues. The ability to systematically
test many of these hypotheses in the near future will be possible
given the proliferation of deeply characterized data sets (e.g.,
GTEx [http://commonfund.nih.gov/GTEx/] and MuTHER [http://
www.muther.ac.uk/]).
While the TCGA was primarily envisioned as a somatically
oriented database, we utilized both germline and somatic infor-
mation to reveal how the data can be used to shed light on risk
alleles discovered through GWAS. Our analyses highlight the
power and promise of using publicly available data sets to derive
biologic insights in unanticipated ways.
EXPERIMENTAL PROCEDURES
Data Sets
The breast cancer data set was downloaded from ‘‘The Cancer GenomeAtlas’’
data portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). The germlinegenotypes are measured from blood-derived DNA samples and the expres-
sion profile, the somatic copy number, and methylation are measured and in-
ferred from matched tumor samples (Table S1).
Verification of Ancestry
We selected 250,160 SNP loci with allele frequencies above 0.05 from the SNP
profiles of 407 breast cancer samples (the subjects) and 415 HapMap cell lines
(the controls). Then we combined the profiles of the 259,001 SNPs from the
breast cancer samples and the HapMap cell lines. The combined SNP profiles
were run on the EIGENSTRAT program and the top two principal components
(PC1 and PC2) were retrieved. From the 273 samples that coclustered with
HapMap CEU controls, we further selected 171 cases with high ESR1 expres-
sion levels (above 1) and 48 cases with low ESR1 expression (below 0) with
both segmented copy number and methylation measures available.
The Somatic Copy Number and Methylation of Transcripts
To determine the copy-number changes for a given transcript, we retrieved the
segmented copy-number scores of the tumor sample and the paired-normal
control from the level 3 TCGA data, which were both inferred from the Affyme-
trix SNP 6.0 platform. Then for each transcript, we calculated the average of
the segmented copy-number scores of the genetic interval between the
transcription start and end sites as the gene-based somatic copy-number
measure (Figure S4A).
The CpG methylation measure of each sample was profiled using the
HumanMethylation27K array by Illumina, which assays 27,578 CpG sites per
sample. These 27,578 sites represent 14,475 consensus-coding sequences
across the genome, providing approximately two CpG assays per gene, with
increased targeting of cancer-related genes. Then the CpGmethylation status
was determined by discretization CpG methylation measure with cut-off
values of 0.2, 0.4, and 0.6 (Figure S4B).
Association Analyses
In the cis- or local eQTL analysis we evaluated the associations between the
genotype at a given SNP locus and transcripts located within a 2 Mb interval
(1 Mb range up- and downstream). We excluded 90,238 SNP loci with minor
allele frequency < 0.05 and 396 genes with low expression levels—absent calls
in more than 90%of the samples. The expression profile of each gene was first
adjusted for somatic copy-number effects and CpGmethylation using a multi-
variate linear model. The p value corresponds to the regression coefficient
based on the residual expression level and the germline genotype.
We performed cis-eQTL analysis between 816,362 SNP loci (22 autosomes
andXchromosome) andcorrespondingmRNAtranscripts inER-positivebreast
cancer and ER-negative breast cancer, respectively. To control for the false
predictions, we excluded genes with absent call in over 90% of the samples
and genes of which the probes sets are affected by one or multiple known
SNP loci.Wealsoexcluded theHLA locusgiven thehigh levelsof polymorphism
in this region. The Benjamini-Hochberg method was used to correct the raw
p values and a significant association was based on a threshold of FDR of 0.1.
We assessed 15 previously reported breast cancer risk loci for the regulatory
potential in gene expression of breast cancer cells (Table S4). Any variant that
achieved p < 5 3 108 was selected. To adjust for the effects of somatic
factors, we performed multivariate linear regression of the tumor gene expres-
sion on somatic copy number and methylation and used the scaled residuals
as adjusted measures of gene expression. Then, a second regression of the
adjusted gene expression on the germline genotypes of each of the 15 risk
loci was performed.Cell 152, 633–641, January 31, 2013 ª2013 Elsevier Inc. 637
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Figure 3. AI of the ESR1, MYC, and KLF4 Transcription Factors by Breast Cancer Risk Genotypic Status
(A–C) Allelic specific expression measures of three TFs were derived from RNA sequencing of 177 TCGA breast cancer samples. The association between ESR1,
MYC, and KLF4 and the corresponding risk loci of (A) 6q25 (rs2046210), (B) 8q24 (rs418269), and (C) 9q31 (rs471467) were evaluated using the F-test.
Please see also Figures S3 and S4C.The significance of the association between a given risk locus and a gene is
given by the test p value corresponding to the regression coefficient of the
genotype. We called significant associations based on a p value threshold of
0.05. The genes associated with a risk locus at a given significant level are
then defined as the target genes of the locus.
Motif Analysis
For each risk locus, we selected the target genes based on significant
associations (p < 0.05). Then for each of the target genes, we selected
1–50 kb regions on both sides of the transcription start site as putative
enhancer regions. We next retrieved all the sites overlapping the DHS peaks
in the ENCODEMCF-7 DNaseI-seq data generated by the Stamatoyannopou-
los group (Birney et al., 2007) (http://hgdownload.cse.ucsc.edu/goldenPath/
hg19/encodeDCC/wgEncodeUwDnase/). Thus for each risk locus, we ob-
tained a set of DNA sequences from the putative enhancer regions of the
target genes. To control for directional regulatory effects, we considered
upregulated and downregulated target genes separately. Then we identified
the binding motifs of known TFs from databases embedded in cistrome,
including Transfac, JASPAR, UniPROBE (pbm), and hPDI (Liu et al., 2011),
which are significantly overrepresented in these sites (p < 1 3 106). We
further mandated that the TF whose motif was enriched in the target genes
be located within 1 Mb range of the corresponding risk locus. If a transcription
factor satisfies these criteria, we considered it as a candidate for empirical 3C
validation.
To verify that the ESR1 binding site is enriched in the 476 target genes of
6q25 risk locus, we randomly sampled the entire genome 1 million times.
Each time, we picked up 476 genes and counted the occurrence of the
ESR1 binding site in the putative enhancer regions (1 kb to 50 kb) according
to the ChIP-seq study. Then we compared the number of ESR1 binding sites
found in the random gene sets to that of the 476 6q25 target genes to compute
a simulated p value for enrichment.
Determination of AI and Correlation with Risk Allele Status
One hundred seventy-seven breast cancer samples with Caucasian ancestry
were selected from the TCGA database using EIGENSTRAT. The correspond-
ing RNA-sequencing data sets are available in BAM format from ‘‘Cancer
Genomics Hub’’ (CGHub) (https://cghub.ucsc.edu/). We marked all the exonic
SNP loci (marker SNP, Table S6) mapping to the three TF genes (ESR1,MYC,
and KLF4) based on National Center for Biotechnology Information dbSNP
build 135. Then for each sample j, we retrieved all the RNA-sequencing reads
mapped to themarker SNP locus i and counted for the occurrence of reference
(Aij) and alternative (Bij) alleles.
We excluded all SNP loci with low coverage (less than 153), homozygosity
(only one allele present in the mapped reads), and somatic copy-number
changes (copy-number measure 1.5–2.5). For each individual and for a given638 Cell 152, 633–641, January 31, 2013 ª2013 Elsevier Inc.transcribed SNP, we calculated a measure of allelic imbalance m given by
Equation 3:
ıij =
maxðAij ;BijÞ
Aij +Bij
(Equation 3)
Marker SNP loci with extreme major allele fraction (above 0.8) are excluded
as many of these loci are falsely called homozygous by sequencing errors.
When multiple SNP loci were found for a gene in sample j, the average
allelic imbalance across all of the marker SNP loci was used to represent
that gene.
For each of the three breast cancer risk loci and corresponding TF, we
assessed the association between mij and the heterozygosity (AB versus AA
and BB) using F-test p values (Figure S3).
In order to address the reference bias introduced by aligning sequenc-
ing reads to the reference genome, we also examined the distribution of the
reference allele fraction for all the exonic SNP loci that have been used
to determine AI status, which showed no bias toward the reference allele
(Figure S4C).
3C and PCR
MCF7 cells were purchased from ATCC and grown in estrogen-depleted
media for 3 days and treated with 10 nM of 17b-estradiol for 45 min as per-
formed in Shang and Brown (2002). A 3C library was then prepared as previ-
ously described (Pomerantz et al., 2009). Briefly, after hormone treatment,
MCF7 cells were trypsinized, fixed with 1% formaldehyde, and lysed with
3C lysis buffer (10 mM TrisHCl [pH 8], 10 mM NaCl, 0.2% Nonidet P-40).
The pelleted cell nuclei were resuspended in restriction butter with SDS (final
concentration 0.1%) and incubated for 10min at 65C. Then, Triton X-100 (final
concentration 1%) and HindIII 160 U per 1 3 106 cells were added and incu-
bated for 24 hr at 37C on a rotating platform. The digested samples were
added to the 3C ligation mix buffer with T4 DNA ligase and incubated for
24 hr at 16C. The ligated samples were decrosslinked at 65Cwith proteinase
K overnight and were Phenol/Chloroform extracted, EtOH precipitated, and
desalted. Target primers were designed against HindIII-digested fragments
within or close to DHS around SNPs in the region of risk loci and anchor
primers were designed against the fragments cut by HindIII in the TF
promoters (primers available upon request). PCR was performed using Taq
polymerase (QIAGEN), 3C library, and the oligonucleotides listed in Table
S3. PCR conditions were as follows: 5 min at 94C (20 s at 94C, 20 s at
57C, and 30 s at 72C) 3 42 cycles, and 10 min at 72C for extension. Seven
microliters of PCR samples were loaded on the 1.7% agarose gel. The PCR
products were then gel purified and sequenced. Since spurious interactions
are typically undetectable beyond 150 kb, the ESR1 and KLF4 ligation frag-
ments represent bona fide interactions.
Figure 4. 3CDemonstrates Physical Interactions between the 6q25Risk Locus and theESR1Promoter and the 9q21Risk Locus and theKLF4
Promoter
(A) The top panel shows screenshots of the restriction fragments used for the 6q25/ESR1 interaction. These fragments are separated by approximately 170 kb.
The lower left panel shows the gel image of the ligation band. The 263 base pair band is visualized only in the sample with ligase (+Lg) and no band is seen in the
negative control sample without ligase (-Lg). The lower right panel demonstrates sequence verification of the +Lg band, confirming this interaction.
(B) The 9q21 risk locus and KLF4 physically interact over a distance of 640 kb.
Please see also Figure 3 and Table 1.
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Additional Information
The results published here are in whole or part based upon data generated by
The Cancer Genome Atlas Pilot Project established by the NCI and NHGRI.
Information about TCGA and the investigators and institutions that constitute
the TCGA research network can be found at http://cancergenome.nih.gov. All
the data we used for this study were generated and available from TCGA, in
which proper patient consent guidelines have been applied. The request for
TCGA data access [#11820-4] was approved by the TCGA Data Access
Committee.
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Supplemental Information includes four figures and seven tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cell.2012.12.034.
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